Loading cancer entity…
Loading cancer entity…
Clinical trials
103 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (20)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01829711 | Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia | completed | Phase 3 | 80 | MedImmune LLCINDUSTRY | 14 | Apr 8, 2020 | clinicaltrials |
| NCT00040846 |
| Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
| completed |
| Phase 2 |
| 60 |
| Fred Hutchinson Cancer CenterOTHER |
| 2 |
| Jan 29, 2020 |
| clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00014235 | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | completed | N/A | 160 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT00003196 | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma | completed | N/A | 63 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 27, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT00861510 | A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies | completed | Phase 1 | 16 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 3, 2019 | clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT00005799 | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | N/A | 55 | Fred Hutchinson Cancer CenterOTHER | 2 | Sep 10, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma | terminated | N/A | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT00586924 | A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia | completed | Phase 1 | 49 | MedImmune LLCINDUSTRY | 2 | Apr 2, 2019 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00898079 | Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer | completed | — | 2,545 | Children's Oncology GroupNETWORK | 6 | Jul 19, 2018 | clinicaltrials |
| NCT01053494 | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | completed | N/A | 80 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 1 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT01254578 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2017 | clinicaltrials |
| NCT01720758 | Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease(B-RAF V600E) | completed | — | 20 | HaEmek Medical Center, IsraelOTHER | 0 | Aug 11, 2017 | clinicaltrials |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | N/A | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00112593 | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | completed | N/A | 5 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00408681 | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant(GVHD) | completed | N/A | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT02883946 | Rituximab in Hairy Cell Leukemia: a Multicenter Retrospective Study(RITUX-LEUKEMIA) | completed | — | 41 | CHU de ReimsOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT01748721 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00924040 | Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 29, 2015 | clinicaltrials |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection | terminated | Phase 1 | 72 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2015 | clinicaltrials |
| NCT01959477 | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant | completed | Early Phase 1 | 33 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | withdrawn | N/A | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | May 7, 2015 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 2 | May 1, 2014 | clinicaltrials |
| NCT01231919 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 2 | Apr 29, 2014 | clinicaltrials |
| NCT01233921 | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer | completed | N/A | 6 | Martin, PaulOTHER | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00458731 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | completed | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2014 | clinicaltrials |
| NCT00058227 | Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 0 | Jul 9, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Oct 19, 2020source: clinicaltrials